Iambic Therapeutics (NASDAQ:IAM) Shares Gap Up – Should You Buy?

Shares of Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report) gapped up before the market opened on Wednesday. The stock had previously closed at $14.22, but opened at $15.00. Iambic Therapeutics shares last traded at $15.20, with a volume of 113,371 shares.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Iambic Therapeutics in a report on Tuesday, November 10th. They issued a “buy” rating and a $35.00 price target on the stock. Wall Street Zen raised Iambic Therapeutics to a “hold” rating in a report on Saturday, November 7th. Zacks Research began coverage on Iambic Therapeutics in a research report on Tuesday, November 10th. They issued a “hold” rating for the company. Bank of America began coverage on Iambic Therapeutics in a research note on Monday, November 9th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, JPMorgan Chase & Co. assumed coverage on Iambic Therapeutics in a research note on Monday, November 9th. They issued an “overweight” rating and a $22.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.25.

View Our Latest Stock Report on Iambic Therapeutics

Iambic Therapeutics Price Performance

Iambic Therapeutics (NASDAQ:IAM – Get Free Report) last posted its earnings results on Monday, November 16th. The company reported ($6.23) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($5.90). The firm had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $42.50 million. On average, sell-side analysts forecast that Iambic Therapeutics, Inc. will post -1.83 earnings per share for the current year.

Insider Buying and Selling

In other Iambic Therapeutics news, Director Evan Lockwood Rachlin acquired 718,750 shares of the business’s stock in a transaction that occurred on Friday, October 16th. The stock was bought at an average cost of $16.00 per share, with a total value of $11,500,000.00. Following the acquisition, the director owned 2,588,248 shares in the company, valued at approximately $41,411,968. This represents a 38.45% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

About Iambic Therapeutics

(Get Free Report)

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.

Read More

Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.